Bruker Corporation $BRKR Shares Purchased by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group increased its Bruker stake by 86.2% in the second quarter, acquiring 653,007 additional shares and bringing its holdings to 1.41 million shares valued at about $84.9 million. Institutional investors and hedge funds collectively own 79.52% of Bruker.
• Bruker reported quarterly EPS of $0.49, exceeding estimates of $0.38, while revenue rose 5.2% year over year to $838.5 million but fell short of forecasts. The company maintained fiscal 2026 EPS guidance of $2.10–$2.15.
• Analyst sentiment is broadly positive, with the stock carrying a “Moderate Buy” consensus rating and several firms raising price targets. Bruker also declared a quarterly dividend of $0.05 per share, equal to a 0.4% annualized yield.

Alyeska Investment Group L.P. boosted its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 86.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,410,164 shares of the medical research company's stock after acquiring an additional 653,007 shares during the period. Alyeska Investment Group L.P. owned about 0.93% of Bruker worth $84,864,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada raised its position in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after purchasing an additional 9,501 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Bruker in the 1st quarter worth about $262,000. Goldman Sachs Group Inc. lifted its position in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock valued at $61,162,000 after purchasing an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock valued at $15,285,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth boosted its stake in Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock valued at $469,000 after purchasing an additional 6,008 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

BRKR opened at $57.08 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm has a market cap of $8.70 billion, a PE ratio of -81.54, a P/E/G ratio of 1.75 and a beta of 1.28. The business has a fifty day simple moving average of $58.77 and a 200-day simple moving average of $48.00. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio (DPR) is -28.57%.

Analyst Ratings Changes

Several analysts recently commented on the company. Zacks Research upgraded Bruker from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 4th. Leerink Partners increased their price target on Bruker from $60.00 to $70.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. raised their price target on Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a report on Monday, June 8th. Guggenheim lifted their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Finally, Barclays lifted their price objective on shares of Bruker from $53.00 to $60.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source